Filed by Automated Filing Services Inc. (604) 609-0244 - Response Biomedical Corp. - Exhibit 4.6







December 3, 2003


 Response Biomedical Corp. 

  8081 Lougheed Highway 

  Burnaby, British Columbia 

  V5A 1W9 


Dear Sirs:


 As per our recent discussions, I agree to adjust my consulting
  schedule for Response Biomedical during the period between December 1, 2003
  and January 31, 2004 from 3 days to 2 days per week. Accordingly, I understand
  that my consulting fee of US$9,750 per month will be prorated (as provided in
  the consulting agreement) by 1/3rd to US$6,500 per month for the
  above period. 

 Further, for the same period I agree to defer receipt of 50%
  of the adjusted consulting fee (US$3,250 per month for two months) until such
  date as mutually agreed to by Response and myself. It is my understanding that
  the deferred portion of my salary will be accrued and subsequently paid to me
  on such date(s) and in a form as mutually agreed by us. All other terms and
  conditions of my Consulting Contract dated May 1, 2003 remain unchanged. 

 Thereafter, beginning February 1, 2004 I shall resume working
  for Response three days a week at my original consulting fee of US$9,750 per
  month. 


Yours truly,



"Paul C. Harris, PhD"


 Paul C. Harris, PhD 

  Vice President, Research and Development 








CONSULTING AGREEMENT 


 THIS CONSULTING AGREEMENT made the 1st day of May 2003
  between RESPONSE BIOMEDICAL CORP. (“the Company”) of 8855 Northbrook
  Court, Burnaby, British Columbia, V5J 5J1 and Micron Engineering owned by Paul
  C. Harris, PhD (the “Consultant”) of 3022 184th Place SE,
  Bothell, Washington 98012. 

 This Agreement sets forth the terms upon which the Company
  engages the Consultant. The parties hereto agree as follows:

	1.0 	NATURE OF ENGAGEMENT 

	 	 
	1.1 	Duties. The duties and responsibilities of
        the Consultant shall primarily include, but not be limited to, directing
        the development and commercialisation of the RAMP technology. The Consultant
        agrees to have Paul Harris spend as much time as is reasonably required,
        nominally twelve days per month, in the Company’s facilities
        in Burnaby, B.C. or other designated locations, during the term of this
        Agreement. The Consultant may be required, from time to time, to participate
        in trade shows, fund-raising or partnering meetings off-site. 

	 	 
	1.2 	Title. Paul C. Harris, PhD will continue to
        have the title “Vice President, Research and      Development”
        for the term of this Agreement and report to the Chief Executive Officer.
        1.3 Term. This Agreement shall be effective as of May 1, 2003
        and shall expire on April 30, 2004.

	 	 
	 2.0 	CONSULTANT’S COMPENSATION 

	 	 
	2.1	Fees. The Company agrees to pay the Consultant
        a consulting fee of $140,000 U.S. per year based on an average
        of 12 workdays per month, payable in equal monthly instalments. This amount
        may be pro-rated for different numbers of workdays by mutual agreement.
      

	 	 
	2.2 	Expenses. Upon the submission of expense reports
        in such form as requested by the Company, the Consultant shall be reimbursed
        for all reasonable and actual business expenses, including the cost
        of a cellular phone that will not exceed US$150 per month. The
        Company will also reimburse the Consultant for all reasonable and actual
        expenses related to travel while on Company business and lodging while
        in Vancouver. 

	 	 
	2.3	Incentive Bonus Plan 

       The Consultant will be entitled to earn up to 20%
        of the annual salary through the Company’s proposed milestone-based,
        incentive bonus plan (“Plan”) which is expected to receive prior
        approval by the Board of Directors and come into effect upon the Company
        securing sufficient financing to meet its forecasted funding requirements
        to reach positive net cash flow. The milestones that trigger bonuses under
        the Plan shall be mutually agreed to by the Consultant and the President
        and shall be approved by the Board of Directors or the Compensation Committee.
      










 - 3 - 

	2.4	Stock Options  

       The Consultant shall be granted stock options from time
        to time in accordance with the Company’s Stock Option Plan. 

	 	 
	2.5	Other Benefits  

       In addition to any other compensation or benefits to
        be received by the Consultant pursuant to this Agreement, the Consultant
        shall be entitled to participate in all executive benefits which the Company
        may from time to time provide to its senior executives, including the
        granting of stock options as approved by the Board or Committee. 

	 	 
	3.0 	TERMINATION OF ENGAGEMENT 

	 	 
	3.1 	Termination. Either party may terminate the
        engagement with three months notice. 

	 	 
	3.2	Conflict of Interest. This Agreement may be
        terminated if a conflict of interest arises as a result of the Consultant's
        direct or indirect association with a third party that competes, or may
        compete, with the Company. 

	 	 
	3.3 	Exit Interview. In the event of termination
        of this Agreement by either party the Consultant will meet with the Company
        for an interview. At that time the Consultant shall deliver to the Company
        all documents in the Consultant's possession including all notes, graphs,
        publications, data and other materials obtained or produced by the Consultant
        during his engagement. 

	 	 
	3.4	Continuing Obligations. The obligations as
        set out in Article 5 will survive the termination of engagement. 

	 	 
	4.0 	OWNERSHIP OF WORK PRODUCT 

	 	 
	4.1 	Any and all know-how, ideas, discoveries, inventions,
        improvements, formula, methods, processes, systems, plans and any other
        knowledge or information of a technical or scientific nature or of a business
        nature pertinent to the Company's scientific or business interests whether
        protectable as industrial or intellectual property right or not, which
        the Consultant may conceive, develop or acquire either solely or jointly
        with any other party in furtherance of the engagement with the Company
        will be the sole and exclusive property of the Company. The Consultant
        agrees to assign all patents to the Company and to assist in their issuance
        in accordance with the Company’s patent incentive policy. The Consultant
        will be eligible for any patent incentive bonuses. This section will remain
        in effect for 5 years past the termination of this contract. 

	 	 
	5.0 	CONFIDENTIAL INFORMATION 

	 	 
	5.1 	The Consultant shall abide by the Confidentiality
        and Non-Disclosure Agreement previously entered into by both parties and
        carry out all such policies of the Company placed in effect to establish
        and protect the confidence of all such information; provided however,
        that the exceptions in Section 3.1 thereof shall include data that is
        required to be disclosed by subpoena, order or rule of any court or governmental
        agency, but only to the extent so required. 











 - 4 -

	6.0 	NOTICES 
	 	 
	6.1 	Any notice required to be given hereunder by either
        party shall be deemed to have been well and sufficiently given if mailed
        by prepaid registered mail to, or delivered by courier at, the address
        of the other party hereinafter set forth: 





	   	(a)
	If to Response:
	Response Biomedical Corp.
	 	 	 	8855 Northbrook Court
	 	 	 	Burnaby, B.C. V5J 5J1
	 	 	 	 
	 	(b)
	If to the Consultant:
	Paul C. Harris, Ph.D.
	 	 	 	3022 184th Place SE
	 	 	 	Bothell, WA 98012
	 	 
	 	or at such other address as each party
        may from time to time direct by notice in writing. Such notice shall be
        deemed to have been received, if mailed, on the date stamped as the date
        of receipt and, if delivered, upon the date of delivery. If normal mail
        service is disrupted all notices will be delivered by courier. 

	 	 
	7.0	ENTIRE AGREEMENT 

	 	 
	7.1	If any provision of this agreement is
        invalid or unenforceable, it shall be severed from the agreement and shall
        not affect the enforceability or validity of the remaining provisions
        of this agreement. 

	 	 
	7.2 	With the exception of the Confidentiality
        and Non-Disclosure Agreement previously entered into between the parties,
        this agreement sets forth the entire understanding between the parties
        and no modifications shall be binding unless executed in writing by the
        parties. 

	 	 
	7.3 	The validity, construction and performance
        of this agreement shall be governed by and be interpreted in accordance
        with the laws of the Province of British Columbia. 



IN WITNESS WHEREOF the parties hereto as of the day and year first above written
  have executed this agreement. 

	RESPONSE BIOMEDICAL CORP.	 	CONSULTANT:
	 	 	 
	"William J. Radvak"	 	"Paul C. Harris, Ph.D."
	William J. Radvak	 	Paul C. Harris, Ph.D.
	President & CEO	 	Owner, Micron Engineering
	 	 	 
	Date:June 24, 2003	 	Date:June 24, 2003












- 5 -


Addendum to Consulting Contract of Micron Engineering

 Whereas Response Biomedical Corp. (“the Company”)
  is funded primarily by investor funds and these funds are uncertain and, at
  times, in short supply, and;

 Whereas the agreed upon fee in section 2.1 is normal and customary
  for the Consultant and is normal and customary for this type of work, the Company
  and the Consultant agree to the following:


  	The Company will pay only a portion of the agreed upon amount each month.
      The Consultant will accept only a portion of the agreed upon amount each
      month.

    
	No future claim for funds will be made.

    




	The amount to be paid will be $117,000 per year for 12 working days
    per month (average), to be paid in monthly instalments.

  
	The agreed upon amount may be amended at anytime by mutual agreement of
    both parties.


 IN WITNESS WHEREOF the parties hereto as of the day and year written herein
  have executed this agreement:



	RESPONSE BIOMEDICAL CORP.	 	CONSULTANT:
	 	 	 
	"William J. Radvak"	 	"Paul C. Harris, Ph.D."
	William J. Radvak	 	Paul C. Harris, Ph.D.
	President & CEO	 	Owner, Micron Engineering
	 	 	 
	Date:June 24, 2003	 	Date:June 27, 2003